Graft versus host disease happens following transplantation of a stem cell or bone marrow. High-dose therapy kills cancer cells along with destroying healthy cells at the same time. In the reconstruction of damaged cells surrounding cancer tumors, bone marrow transplant and stem cell treatments are used. Usually later high-dose therapy, the patient gets a donor’s bone marrow through a drip that resumes blood cell production. Graft versus host disease happens when certain white blood cell kinds are present. This is triggered by the transplanted cells (graft) see the body (host) of the recipient as exotic, so transplanted cells attack the host body. Diagnosing who may develop GvHD after a transplant is difficult. In a few instances, mild GvHD form is noted. While GvHD may be deadly in some instances. GvHD does not happen when the recipient gets autologous transplantation of their own cells. In order to understand how strictly they match the recipient, cells from potential donors are tested before a transplant. GvHD’s chances are decreased, or when the match is relatively close, symptoms will be milder.
The global graft-versus-host disease market is extremely fragmented, with significant players using multiple approaches such as new product launches, expansions, contracts, joint ventures, alliances, acquisitions, and others to boost their footprints in this market. Some of the major players in the worldwide graft vs. the host disease therapy industry are Eli Lilly, Abbott, Takeda Pharmaceutical, Merck & Co., Astellas Pharma, AbbVie, F. Hoffmann-La Roche, Pfizer, Bristol-Myers Squibb, and Novartis AG among others.
Market Dynamics: Drivers, Restraints, Opportunities Challenges
- Large unmet needs for the management of GVHD
According to the Center for International Blood and Marrow Transplant Research, around 25,000 allogeneic stem cell transplants are performed globally per year, affecting half or more recipients, nearly half of these cases could have been avoided with the availability of adequate medical equipment and devices for healthcare procedures. It is anticipated that this substantial number will serve as a major driver of market growth. Increasing product approval for GVHD and increased diagnostic rates of disease will drive demand over the forecast period
- Limited available treatment drugs will serve as prominent opportunity for novel drug development.
Due to the scarcity of any approved drugs on the market, the GvHD industry mainly includes off-label therapies. As yet, only three therapies have been endorsed, namely Grafalon (authorized for prophylaxis in Germany), Temcell (authorized for GvHD in Japan) and Imbruvica (authorized for cGvHD in the US). But as the prevalence of disease and market size is anticipated to increase the launch of seven new drugs is expected over the forecast period. Among these seven, most drugs for steroid refractory acute GVHD are being developed.
Get Free Sample Report: https://www.wiseguyreports.com/sample-request/4532900-global-graft-versus-host-disease-market
Graft versus host disease (GVHD) Market by Disease Type
- Acute graft versus host disease (aGvHD)
- Chronic graft versus host disease (cGvHD)
Graft versus host disease (GVHD) Market by Product
- IL2Rα (CD25) inhibitors
- TNFα inhibitors
- Calcineurin inhibitors
- mTOR inhibitors
- monoclonal antibodies
North America, Asia Pacific, Europe, Latin America, and Middle East & Africa can categorize the worldwide graft versus host disease therapy market based on region. Europe has the biggest market share in worldwide market graft versus host disease (GvHD) therapy in terms of region due to advances in medical research, clinical trials, increasing geriatric population with cancer indication. Whereas, due to a high incidence and prevalence rate of worldwide graft versus host disease, it is estimated that North America and Asia Pacific will grow rapidly. For instance, a research study indicates that recipients of hematopoietic stem cell transplantation (HSCT) develop acute GVHD from around 30 percent to 50 percent. That means 5,500 patients per year developing acute GVHD. Some 50% of patients with acute graft versus host disease eventually have chronic graft versus host disease manifestations. The graft versus host disease therapy market in different geographies is fueled specifically by the adoption of modern cancer treatment techniques, increasing awareness of diseases, and increasing the number of medicines for chemotherapy.
Graft versus host disease is a significant cause of stem cell transplant morbidity and mortality. Research results indicate that even after extensive immunosuppressive treatment procedures, 50% to 70% of patients transplanted from unrelated donors and 30% to 50% of patients transplanted from completely matched sibling donors develop some degree of grafts versus host disease. High unmet medical need and limited treatment options will drive the market over the forecast period. Based on geographic analysis the Europe region will hold significant market share over the forecast period, whereas the North America and Asia Pacific regions are anticipated to reflect lucrative growth in near future.
Read Other Reports from our Database :
Table of Contents
- Research Methodology
- Executive Summary
- Market Overview
- Industry Insights
- Graft Versus Host Disease Market, by Disease Type
- Graft Versus Host Disease Market, by Product
- Graft Versus Host Disease Market, by Region
- Competitive Landscape
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.
Ph: +162 825 80070 (US)
Ph: +44 203 500 2763 (UK)